Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Status unconfirmed · Phase 4

Conditions studied: Extracorporeal Membrane Oxygenation Complication, Anticoagulants

In brief

This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in adult patients that require extracorporeal membrane oxygenation (ECMO). Half of the participants will receive heparin and half will receive bivalirudin.

Key facts

Study ID

NCT03965208

Run by

Legacy Health System

People needed

34

Starts

2019-05-23

Expected to finish

2020-12-31

Last updated by the study team

2019-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Require ECMO and systemic anticoagulation as determined by the primary treating physician
• Require anticoagulation to target an activated partial thromboplastin time (aPTT) of 40-60 seconds or 60-80 seconds

You may not qualify if…

• Prior inclusion in this study
• Patients with known or suspected heparin induced thrombocytopenia
• Systemic anticoagulation at Legacy for ≥ 24 hours during ECMO immediately prior to study enrollment
• Allergy to heparin or related products or bivalirudin
• Known anti-thrombin deficiency
• Selection of a non-standard aPTT target range

Where it is running

• Legacy Health System — Portland, Oregon, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.